Technical Analysis for ACTU - Actuate Therapeutics, Inc.

Grade Last Price % Change Price Change
C 8.99 4.78% 0.41
ACTU closed down 3.6 percent on Wednesday, November 20, 2024, on 84 percent of normal volume.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent N/A Up Up

Date Alert Name Type % Chg
Fell Below 20 DMA Bearish 4.78%
20 DMA Support Bullish 3.57%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 3.57%
NR7 Range Contraction 3.57%
Narrow Range Bar Range Contraction 3.57%
MACD Bearish Signal Line Cross Bearish 5.15%
20 DMA Support Bullish 5.15%
Bearish Engulfing Bearish 5.02%
Gapped Up Strength 5.02%
Shooting Star Candlestick Bearish -0.33%

   Recent Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Actuate Therapeutics, Inc. Description

Actuate Therapeutics provides advanced research for the treatment of high-impact cancers and neurodegenerative diseases. It is a private biopharmaceutical company focused on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis and neurodegeneration. The company aims to discover, develop, and commercialize new agents that target GSK-3?. Actuate Therapeutics is currently advancing its lead molecule, 9-ING-41, toward the clinic in 2017. Ongoing research has demonstrated significant anti-tumor activity in many in vivo models of difficult-to-treat cancers, including cancers of the brain, pancreas, lung, and breast. We are unaware of any published research demonstrating the kind of efficacy in treatment-resistant glioblastoma that we have been able to achieve with 9-ING-41. Importantly, the toxicity and pharmacokinetic profiles of the drug candidate are quite attractive.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Oncology Treatment Of Cancer Inflammatory Diseases Neurodegenerative Diseases Glioblastoma Aging Associated Diseases Fibrosis Neurodegenerative Disease

Is ACTU a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 10.162
52 Week Low 5.52
Average Volume 47,611
200-Day Moving Average 0.00
50-Day Moving Average 7.88
20-Day Moving Average 8.69
10-Day Moving Average 8.77
Average True Range 0.67
RSI (14) 52.38
ADX 15.42
+DI 23.72
-DI 17.79
Chandelier Exit (Long, 3 ATRs) 7.87
Chandelier Exit (Short, 3 ATRs) 8.83
Upper Bollinger Bands 9.30
Lower Bollinger Band 8.07
Percent B (%b) 0.41
BandWidth 14.09
MACD Line 0.24
MACD Signal Line 0.27
MACD Histogram -0.0325
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.11
Resistance 3 (R3) 9.17 9.05 9.02
Resistance 2 (R2) 9.05 8.92 9.02 8.99
Resistance 1 (R1) 8.82 8.83 8.76 8.76 8.96
Pivot Point 8.70 8.70 8.67 8.67 8.70
Support 1 (S1) 8.46 8.56 8.40 8.40 8.20
Support 2 (S2) 8.34 8.48 8.31 8.17
Support 3 (S3) 8.11 8.34 8.14
Support 4 (S4) 8.05